A Phase 2 interventional study of HRS-3095 Tablet and HRS-3095 Tablet Placebo in Chronic Spontaneous Urticaria, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.
Among the 34 studies in Chronic Urticaria with a site in China, this one is the 11th largest by planned enrollment of the 30 interventional ones that give a count, is one of 11 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 9 of the 19 other live ones, and was the 29th registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:
Novelty Nobility, Inc. · Sites in China
Ages 18–75 · Healthy volunteers
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Yuhan Corporation · Sites in China, Bulgaria, Poland and 1 more country
Ages 18–75
Jemincare · Sites in China
Ages 18+
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 10
First in 2013; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 110 across the 30 interventional studies, 270 across the 4 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chengdu Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 3 studies filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
10 of the studies in Chronic Urticaria with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07402213Phase 3JemincareTrial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. | 2027-06-07 |
| NCT06604949Longbio PharmaA Study of Single Dose of LP-003 in Healthy Adult Subjects | 2026-11 |
| NCT07005713BeOne MedicinesA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants | 2026-11-30 |
| NCT07613866Chengdu Suncadia Medicine Co., Ltd.A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria | 2026-12 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
Add all 10 to your calendar (.ics) → With an account.
Among the 34 studies in Chronic Urticaria with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HRS-3095 in different doses.
Drug: HRS-3095 Tablet
HRS-3095 blank preparation.
Drug: HRS-3095 Tablet Placebo
HRS-3095 tablet.
HRS-3095 tablet placebo.
Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 4.
Time frame: Up to 4 weeks.
The concentration of HRS-3095 in serum (Cmax)
Time frame: From the beginning of administration to the 4th week.
The time of metabolism of the drug in the serum
The concentration of HRS-3095 in plasma will be determined.
Time frame: From the beginning of administration to the 4th week.
The concentration of HRS-3095 in serum (AUC)
The concentration of HRS-3095 in plasma will be determined.
Time frame: From the beginning of administration to the 4th week.
Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2
Time frame: Up to 4 weeks.
Change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4
Time frame: Up to 4 weeks.
Change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4
Time frame: Up to 4 weeks.
Percentage change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2 and 4
Time frame: Up to 4 weeks.
Percentage change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4
Time frame: Up to 4 weeks.
Percentage change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4
Time frame: Up to 4 weeks.
Proportion of patients with UAS7 ≤ 6 at Week 2 and 4 compared to baseline
Time frame: Up to 4 weeks.
Proportion of patients with UAS7 = 0 at Week 2 and 4 compared to baseline
Time frame: Up to 4 weeks.
Proportion of patients achieving the Minimum Important Difference (MID) in UAS7 at Week 2 and 4
≥ 10-point decrease from baseline.
Time frame: Up to 4 weeks.
Proportion of patients achieving the Minimum Important Difference (MID) in ISS7 at Week 2 and 4
≥ 5-point decrease from baseline.
Time frame: Up to 4 weeks.
Time to achieve the Minimum Important Difference (MID) in UAS7
≥ 10-point decrease from baseline.
Time frame: Up to 4 weeks.
Time to achieve the Minimum Important Difference (MID) in ISS7
≥ 10-point decrease from baseline.
Time frame: Up to 4 weeks.
Change in 7-day Angioedema Activity Score (AAS7) from baseline at Week 2 and 4
Time frame: Up to 4 weeks.
Change in Urticaria Control Test (UCT) from baseline at Week 4
Time frame: Up to 4 weeks.
Proportion of participants with UCT ≥ 12 at Week 4 compared to baseline
Time frame: Up to 4 weeks.
Change in Dermatology Life Quality Index (DLQI) from baseline at Week 4
Time frame: Up to 4 weeks.
Proportion of participants with DLQI = 0 or 1 at Week 4 compared to baseline
Time frame: Up to 4 weeks.
Adverse events
Time frame: From the beginning of administration to the 8th week.
Plasma concentrations of HRS-3095 and its metabolites
Time frame: From the beginning of administration to the 4th week.
Relative change from baseline in serum total immunoglobulin E (IgE)
Time frame: From the beginning of administration to the 4th week.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.
Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-3095
Chengdu Suncadia Medicine Co., Ltd. →